Annexin Pharmaceuticals AB (ANNX) - Total Liabilities

Latest as of December 2025: Skr5.22 Million SEK ≈ $562.19K USD

Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has total liabilities worth Skr5.22 Million SEK (≈ $562.19K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Annexin Pharmaceuticals AB operating cash flow efficiency to assess how effectively this company generates cash.

Annexin Pharmaceuticals AB - Total Liabilities Trend (2014–2025)

This chart illustrates how Annexin Pharmaceuticals AB's total liabilities have evolved over time, based on quarterly financial data. See ANNX book value for net asset value and shareholders' equity analysis.

Annexin Pharmaceuticals AB Competitors by Total Liabilities

The table below lists competitors of Annexin Pharmaceuticals AB ranked by their total liabilities.

Company	Country	Total Liabilities
eEducation Albert AB ST:ALBERT	Sweden	Skr83.57 Million
Dycasa SA BA:DYCA	Argentina	AR$23.74 Billion
Energoinstal S.A. WAR:ENI	Poland	zł46.51 Million
Delixy Holdings Limited Ordinary Shares NASDAQ:DLXY	USA	$22.30 Million
Max Resource Corp V:MAX	Canada	CA$2.50 Million
Sirona Biochem Corp V:SBM	Canada	CA$4.27 Million
Biovie Inc NASDAQ:BIVI	USA	$3.24 Million
Calibre PA:ALWIN	USA	€18.95 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Annexin Pharmaceuticals AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Annexin Pharmaceuticals AB market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.47	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.21	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.17	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Annexin Pharmaceuticals AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Annexin Pharmaceuticals AB (2014–2025)

The table below shows the annual total liabilities of Annexin Pharmaceuticals AB from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr5.22 Million ≈ $562.19K	-1.86%
2024-12-31	Skr5.32 Million ≈ $572.84K	-33.04%
2023-12-31	Skr7.95 Million ≈ $855.44K	+21.81%
2022-12-31	Skr6.53 Million ≈ $702.30K	+7.71%
2021-12-31	Skr6.06 Million ≈ $652.05K	+34.05%
2020-12-31	Skr4.52 Million ≈ $486.42K	-0.59%
2019-12-31	Skr4.55 Million ≈ $489.33K	-26.52%
2018-12-31	Skr6.19 Million ≈ $665.93K	-3.45%
2017-12-31	Skr6.41 Million ≈ $689.71K	-18.72%
2016-12-31	Skr7.88 Million ≈ $848.55K	+140.18%
2015-12-31	Skr3.28 Million ≈ $353.30K	+234.61%
2014-12-31	Skr981.14K ≈ $105.59K	--

About Annexin Pharmaceuticals AB

ST:ANNX Sweden Biotechnology

Market Cap

$11.24 Million

Skr104.47 Million SEK

Market Cap Rank

#26581 Global

#577 in Sweden

Share Price

Skr14.80

Change (1 day)

-1.33%

52-Week Range

Skr0.27 - Skr37.00

All Time High

Skr37.00